Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. filed a current report to note it issued a press release with its financial results for the third quarter ended September 30, 2025.
The press release, dated November 6, 2025, is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” limiting its treatment under certain securities law liability provisions.
Maze Therapeutics, Inc. filed a Rule 424(b)(3) prospectus covering the resale of up to 9,231,092 shares of common stock by selling stockholders. This includes 4,000,002 Initial Shares and up to 5,231,090 Warrant Shares issuable upon exercise of pre-funded warrants issued in a September 2025 private placement.
The company is not selling any securities in this prospectus and will not receive proceeds from sales by the holders. Upon any cash exercise of the pre-funded warrants (exercise price $0.001 per share), the company would receive the exercise price. The shares may be sold at market or negotiated prices through brokers, dealers, agents, or direct sales. The warrants include a 4.99% or 9.99% beneficial ownership cap. As context, shares outstanding were 48,076,885 as of September 30, 2025. Examples of registered resale amounts include Entities Affiliated with Baker Brothers 1,538,556 and Janus Henderson 1,230,769. Common stock trades on Nasdaq as MAZE.
Maze Therapeutics (MAZE): Form 4 insider activity
Affiliates of Third Rock Ventures reported a pro rata, for-no-consideration distribution of 1,600,000 shares of Maze Therapeutics common stock on November 4, 2025, noted with transaction code J and described as exempt under Rules 16a-13 and 16a-9. Following the distribution, the filing shows 4,473,958 shares beneficially owned directly and 950,800 shares beneficially owned indirectly, with relationships indicated including director and 10% owner statuses and standard beneficial ownership disclaimers among the TRV entities.
Maze Therapeutics (MAZE) reported an insider transaction by a director. On 10/23/2025, the reporting person made a gift of 28,423 shares of common stock, recorded at $0 as a no‑consideration transfer exempt under Rule 16b‑5.
Following the transaction, the filer beneficially owned 29,624 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is trustee.
Maze Therapeutics, Inc. (MAZE) filed a preliminary Form S-1 covering the resale of up to 9,231,092 shares of common stock by selling stockholders. The shares comprise 4,000,002 initial shares and up to 5,231,090 shares issuable upon exercise of pre-funded warrants issued in a September 10, 2025 private placement.
The company is not selling any securities in this offering and will not receive proceeds from stockholder sales; it would receive only the $0.001 per‑share exercise price if any pre-funded warrants are exercised for cash. Sales may occur from time to time after effectiveness at market or negotiated prices through brokers, underwriters, or direct sales.
Examples of per‑holder amounts include Entities Affiliated with Baker Brothers 1,538,556 and Entities Affiliated with Janus Henderson 1,230,769. Pre‑funded warrants include a 4.99% or 9.99% beneficial ownership cap. MAZE trades on Nasdaq Global Market under “MAZE.”
Maze Therapeutics, Inc. director Herve Hoppenot was granted a stock option on 10/06/2025 to buy 36,000 shares of common stock at an exercise price of $27.52 per share. The option vests monthly at 1/36 of the award beginning on 11/06/2025 and on each monthly anniversary thereafter, subject to continued service, and expires on 10/05/203536,000 options directly. The filing was signed by an attorney-in-fact on 10/07/2025.
Maze Therapeutics director Herve Hoppenot filed an Initial Statement of Beneficial Ownership (Form 3) reporting no securities beneficially owned as of 10/06/2025. The filing lists his role as a Director and was signed by an attorney-in-fact on 10/07/2025. The form shows no direct or indirect holdings and no derivative positions reported.
Maze Therapeutics appointed Mr. Hoppenot to the Board and named him Chairman effective October 6, 2025. As a non-employee director he will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $30,000 annual chairman retainer for the remainder of the year under the companys existing policy. The Board also granted an option to purchase up to 36,000 shares of common stock (the Option Award), with 1/36th of the underlying shares vesting and becoming exercisable on each monthly anniversary of the Appointment Date, subject to continued service.
The arrangement combines cash retainer compensation paid pro rata for partial-year service with an equity award that vests monthly over 36 months, tying compensation to ongoing service while spreading equity delivery across a multi-year period.
Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, acquired 22,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement, and the award shows 22,000 shares beneficially owned after the grant at a reported price of $0. The RSUs vest 50% on 09/01/2026 and 50% on 09/01/2027, contingent on continued service, and the units do not expire; they vest or are cancelled prior to vesting dates.
Maze Therapeutics insider award: Atul Dandekar, listed as CSBO and officer, was granted 25,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of Maze Therapeutics common stock upon settlement. The award vests in two equal installments: 12,500 RSUs on September 1, 2026 and 12,500 RSUs on September 1, 2027, subject to the reporting persons continued service on each vesting date. The RSUs do not expire and will either vest or be cancelled prior to the vesting dates. After the grant, the reporting person beneficially owns 25,000 shares (directly) from this award. The Form 4 was signed by an attorney-in-fact on 09/24/2025.